Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donan: Durvalumab in resectable NSCLC
NCT03853187Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2019
- Primary completion
- Dec 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Radboud University Medical Center. Primary endpoints: Safety of neo-adjuvant durvalumab at 14 days and Feasibility of neo-adjuvant durvalumab at 42 days. Started Sep 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03853187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03853187.